Scientists continue studying how hemp-derived cannabinoids may support the body’s response to neuroinflammation and neurodegenerative conditions. In the review “Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration,” researchers examined how cannabinoids such as CBD, CBG, and CBC interact with microglia — the immune cells of the central nervous system. When microglia become overactivated, they may contribute to chronic inflammation associated with neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and other neurological disorders. (Scilit)
The review highlighted that non-psychotropic cannabinoids demonstrated anti-inflammatory, antioxidant, and neuroprotective activity in preclinical studies. Researchers found that cannabinoids may help regulate inflammatory signaling pathways, reduce oxidative stress, and support cellular balance within the brain and nervous system. Several cannabinoids also appeared to influence cytokine production and inflammatory mediators connected to microglial activation. These findings continue supporting growing scientific interest in cannabinoids and the endocannabinoid system as important areas of neurological research. (PMC)
Researchers noted that while many findings remain in laboratory and animal models, cannabinoid science continues expanding rapidly as scientists work to better understand how hemp-derived compounds may support neurological wellness and healthy inflammatory response pathways. Studies like this continue highlighting the importance of full-spectrum and multi-cannabinoid formulations, where cannabinoids may work together synergistically through what researchers commonly call the entourage effect. (Scilit)
Source
Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration. Published April 29, 2026. (Scilit) https://pubmed.ncbi.nlm.nih.gov/42121212/